Laboratory aspects of systemic AA amyloidosis
Authors:
T. Pika 1; Z. Heřmanová 2; P. Flodrová 3
Authors place of work:
Hematoonkologická klinika, LF UP a FN Olomouc
1; Ústav imunologie, LF UP a FN Olomouc
2; Ústav klinické a molekulární patologie, LF UP a FN Olomouc
3
Published in the journal:
Klin. Biochem. Metab., 25, 2017, No. 2, p. 56-58
Summary
The aim of the communication is to remind the issue and the clinical significance of selected laboratory parameters used in the diagnosis and monitoring of patients with AA amyloidosis. Correct typing of amyloid masses, exclusion of AL type of amyloidosis, and in particular the clarification of the underlying disease are among the most important aspects in the diagnosis of disease. An essential prerequisite in the treatment of AA amyloidosis is a control of underlying process with a reduction of amyloidogenic serum amyloid A levels.
Keywords:
AA amyloidosis, serum amyloid A, laboratory examination.
Zdroje
1. Sipe, J. D., Benson, M. D., Buxbaum, J. N. et al. Amy-loid fibril protein nomenclature: 2010 recommendations from the nomenclature committe of International Society of Amyloidosis. Amyloid, 2010, 17, p. 101-104.
2. Merlini, G., Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med., 2003, 349, p. 583-596.
3. Merlini, G., Seldin, D. C., Gertz, M. A. Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol., 2011, 29, p. 1924-1933.
4. de Asúa, D. R., Costa, R., Galván, J. M., Filigheddu, M. T., Trujillo, D., Cadinanos, J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin. Epidemiol., 2014, 6, p. 369 – 377.
5. Joss, N., McLaughlin, K., Simpson, K., Boulton-Jones, J. M. Presentation, survival and prognostic markers in AA amyloidosis. Q. J. Med., 2000, 93, p. 535 – 542.
6. Lachmann, H. J. Secondary, AA, amyloidosis. In Gertz, M. A. et al. Amyloidosis: Diagnosis and treatment. New York: Springer Humana Press, 2010, p. 179 – 189.
7. Ryšavá, R. AA amyloidóza. In Ryšavá, R. Systémové amyloidózy a jejich léčba. Praha: Maxdorf, 2013, p. 27 – 45.
8. Westermark, G. T., Fändrich, M., Westermark, P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol., 2015, 10, p. 321 – 344.
9. Kuroda, T., Wada, Y., Nakano, M. Diagnosis and treatment of AA amyloidosis with rheumatoid Arthritis: State of the art. In Sarantseva, S. Amyloidosis – Mechanisms and prospects for therapy. In Tech. ISBN: 978-953-307-253-1. 2011, p. 43 – 62.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2017 Číslo 2
Najčítanejšie v tomto čísle
- Exercise-induced rhabdomyolysis – frequent cause of false diagnosis
- 23 cases of Metformin-induced Metabolic Lactic Acidosis in Patients treated with Metformin
- MedPed project in Czech Republic
- Interpretation difficulties in electrophoresis and immunofixation findings in patients with multiple myeloma after autologous transplantation